DFCI IRB ADVERSE EVENT REPORTING FORM
|
|
- Phyllis Perkins
- 5 years ago
- Views:
Transcription
1 Office for Human Research Studies DANA-FARBER / HARVARD CANCER CENTER DFCI Protocol No.: OHRS USE ONLY HRC: AE #: (unless submitted with an Amendment) Related AM #: DFCI IRB ADVERSE EVENT REPORTING FORM Instructions: This form is for the reporting of adverse events experienced by either (1) local DF/HCC participants or (2) outside Multi-Center Site participants where a DF/HCC investigator is the overall PI. All other adverse events must be reported via IND Safety Reporting mechanism. Please refer to the DFCI IRB policy on reporting AEs to determine which AEs should be reported to the IRB. This form must be submitted as an attachment to an Amendment Form if any protocol and/or consent form changes are required as a result of this reported event. All AEs must be reported via OHRS Submit. No interoffice submissions, faxes or ed reports will be accepted. If this is a report of an event from a multi-center site and a local form is available, please complete Part A, B and Part I, J and attach the local form with this form and submit them both via OHRS submit. Investigators are responsible for knowing the reporting requirement to their institutional risk management department. Please make sure that any reported adverse events, if appropriate, have also been reported to the applicable risk management group. Please call the OHRS with any questions at (617) Part A Study Information Disease Program: Leukemia -OR- Discipline Program: [pull down] [Refer to Protocol Front Sheet for study Disease or Discipline Program name] Protocol Short Title: DFCI ALL Consortium Adult ALL Trial Today s Date: 1/2/2013 Overall Principal Investigator (PI): Daniel DeAngelo, MD, PhD [First Name, Middle Initial, Last Name, Degree(s)] Phone: Pager: Institution: DFCI [PI Institution] Part B Report and Site Information 1. Report Type [Initial, Follow Up 1, Follow Up 2, Follow Up 3]: Initial 2. Date Reported to OHRS: Was this AE reported within the required reporting time period? Yes No - If this Adverse Event (AE) Report was submitted outside of the required reporting time period please explain why and include an appropriate corrective action plan below. Do not file a separate violation. Corrective Action Plan for Delayed Reporting: 3. Reporting Investigator Name: Martha Wadleigh, MD Institution: DFCI [First Name, Middle Initial, Last Name, Degree(s)] Mwadleigh@partners.org Phone: Pager: Site Involved in this Event: DFCI If this site is not participating under the DFCI IRB, please respond to the following question: Is this an outside site participating in a trial where a DF/HCC investigator is the overall PI? Y If yes, you do not have to complete Part C thorough Part H if you attach as supplemental information the local reporting form. Adverse Event Reporting Form Version:
2 N If no, do not complete this form. Please submit your IND/IDE Safety Report to the DFCI IRB as an amendment but only if it meets the OHRS reporting requirements outlined in the DFCI IRB Policy on Receipt and Review of IND/IDE Safety Reports. 5. Name of Study Contact for questions about this submission: Caroline Kokulis Role on Study: Coordinator Institution: DFCI Phone: Pager: Part C Participant Information 1. Participant Study I.D. Number and/or Initials: AY: Date of Serious Adverse Event: 12/28/12 3. Participant Age: Participant Gender: Female 5. Condition Studied: ALL Part D Drugs / Biologics N/A Drug/Biologic Dose Route Schedule FDA IND # and IND Holder Date of First Dose Date of Last Dose (prior to AE) Vincristine 2 mg Intravenous Day 1 N/A 12/7/12 12/7/12 6-MP 50 Oral Days 1-14 N/A 12/7/12 12/20/12 mg/m2/day Dexamethasone 6 Oral Days 1-5 N/A 12/7/12 12/11/12 mg/m2/day BID Methotrexate. 30 mg/m2 Intravenous Day 1 N/A 12/7/12 12/7/12 IT MAH 12 mg, 40 mg, 50 mg Intrathecal Every 18 weeks N/A 10/26/12 10/26/12 Part E Devices N/A Device Name Humanitarian Device? Y N Y N Manufacturer Type of Device FDA IDE # and IDE Holder Date of Procedure Part B Gene: Vector Type: Vector Subtype: Part F Human Gene Transfer Studies Only N/A - 2 -
3 Delivery Method: Dose: Route: Schedule: Date of First Dose: Date of Last Dose: If Other, please specify: - 3 -
4 Part G Descriptive Adverse Event Information Event Description: This patient is a 23 year old female who is enrolled on the trial to treat her Acute Lymphoblastic Leukemia. She is currently in Continuation phase of the study. She was admitted 12/28/12 to BWH with fevers, a non-productive cough, and a green nasal discharged.the patient stated that she had fevers, night sweats, chills, nausea on 12/24/12. Her fever was on 12/27/12. The chest x-ray showed diffuse groundglass opacities bilaterally in the lung bases. She was started on Bactrim PO. This indicated atypical pneumonia, most likely pneumocystis pneumonia. All chemotherapy is being held for at least one week. The patient states that she has been compliant with her Mepron medication. She was treated with steriods and Bactrim, and improved. She was discharged from the hospital on 1/1/13 and will be seen at DFCI on 1/4/13 for follow up. Co-morbidity/Past Medical History: The participant was hospitalized or hospitalization was prolonged. The participant was taking concomitant medications. Medication name(s): Outcome: Still under treatment for event (include date) Date: 12/31/12 Protocol Treatment: Treatment was altered Date: 12/31/12 Part H Adverse Event(s) Please indicate what NCI toxicity version is being used to grade toxicities: CTCAE Version 3.0 For more information please refer to: Adverse Event Event Date Grade (2-5)* Pneumocystis pneumonia Related to Study Treatment? Event Related to Underlying Disease? 12/28/12 3- Severe Definite No Expected/ Unexpected/ Not Applicable [with respect to study treatment] Expected This adverse event is already included in the current consent form(s). Specify the page number(s): Consent pg:
5 No This adverse event is already included in the current consent form(s). Specify the page number(s): No This adverse event is already included in the current consent form(s). Specify the page number(s): No This adverse event is already included in the current consent form(s). Specify the page number(s): Part I Protocol Revisions / Participant Notification 1. Will currently enrolled participants be notified of this adverse event? Y N Explanation: This kind of infection is expected with this study treatment regimen. 2. Are any protocol and/or consent form changes being proposed as a result of this adverse event report: - 5 -
6 Yes. This AE is being reported as an attachment to an Amendment Form submission because protocol and/or consent form changes have been made. No. No changes to the protocol and/or consent form document are required as a result of this report. Part J Statement of Reporting Investigator Form completed by: Name: Caroline Kokulis Role on Study: Coordinator Date: 1/2/2013 Phone: Ckokulis@partners.org The Reporting Investigator assures that the information provided in this submission is complete and accurate. The Overall Principal Investigator (PI name: Daniel DeAngelo, MD, PhD ) has been notified of this event on (date:12/28/12 ). Name of Reporting Investigator: Dr. Martha Wadleigh, MD All Adverse Events reported to the Office for Human Research Studies will be reviewed by an IRB member via an electronic workflow. The electronic workflow will document any expedited review determinations
SWOG
SWOG http://swog.org Page 1 of 5 pages Original Release Date: July 1985 Departments Affected: All Revision Date: April 2018 Introduction SERIOUS ADVERSE EVENTS The timely reporting of serious adverse events
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH
DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH TITLE: SOP #: QA-706 Page: 1 of 7 Applicable Regulations & Guidelines: 21 CFR 312.60 General Responsibilities of
More informationSERIOUS ADVERSE EVENTS
EVENTS Introduction Timely reporting of Serious Adverse Events (SAEs) is required by regulations of the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). Such reporting is not
More informationUSE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH
Policy P.11 Written By: B. Laurel Elder Created: June 3, 2013 Edited Replaces 10-9-2009 Version P.11.4 USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH A. Procedure Contents this procedure
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More information4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationLast Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4
STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Title: Investigational Drug Billing Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4 1. PURPOSE: To assure accurate and
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationTITLE: DF/HCC Investigator-Sponsored Multi-Center TrialsResearch POLICY #: MULTI-100 Page: 11 of 54 Effective Date: 8/31/17 1.
POLICY #: MULTI-100 Page: 11 of 54 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center Trialsresearch
More informationSELF-ASSESSMENT CHECKLIST
SELF-ASSESSMENT CHECKLIST SECTION 1: REGULATORY DOCUMENTATION Staff Documentation 1. Are all versions of the IRB approved protocol on file (including most recent)? 2. Are there CVs/biosketches of PI, Co-Is,
More informationUT SOUTHWESTERN MEDICAL CENTER AT DALLAS INSTITUTIONAL REVIEW BOARD. Emergency Use of an Investigational Drug, Biologic or Device
Emergency Use of an Investigational Drug, Biologic or Device Introduction The emergency use provision in the FDA regulations (21 CFR 56.102d) is an exemption from prior review and approval by the IRB for
More informationResearch Acquired Specimens and/or Data Analysis by an External Site CHECKLIST
DANA-FARBER / HARVARD CANCER CENTER Info Sheet Guidance Office for Human Research Studies Research Acquired Specimens and/or Data Analysis by an External Site CHECKLIST Instructions: Please use this checklist
More informationTITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19
POLICY #: MULTI-100 Page: 1 of 4 1. POLICY STATEMENT: The DF/HCC Sponsor-Investigator, Coordinating Center and External Sites collaborating in DF/HCC Investigator-Sponsored Multi-Center research must comply
More informationExpedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014
Expedited Reporting Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014 Journal of Clinical Research Best Practices Vol. 7, No. 1, January 2011 Can You
More information4.1. Target Accrual Rate: The Target Accrual Goal divided by the Expected Duration (in days) of the trial.
POLICY #: COM-102 Page: 1 of 5 1. POLICY STATEMENT: The Scientific Review Committee (SRC) is responsible for monitoring the accrual and evaluating the scientific merit of each interventional clinical research
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationJoint Research Office of Doncaster & Bassetlaw
Page 1 of 11 Hospitals NHS, Rotherham Doncaster & South Humber NHS and NHS Signatures: Role Name Function Date (DD-MM-YYYY) Signature Author Amy Beckitt Clinical Research Development Manager Reviewer Dr
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationGuidance on Completing Endorsement Forms
DANA-FARBER / HARVARD CANCER CENTER Info Sheet Office for Human Research Studies Guidance on Completing Endorsement Forms In September of 2006, the DF/HCC instituted a requirement that all human research
More informationThe Right Prescription for Working with Investigational Drug Service at BMC
The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationCompassionate Use Navigator Information for Physicians
Compassionate Use Navigator Information for Physicians Contact: Elena Gerasimov, Program Director, Elena@kidsvcancer.org. As a physician, you must have wished there would be more treatment options for
More information1.0 INTRODUCTION AND OVERVIEW
Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationInvestigational New Drug Development Steps for CRCs
Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 08/04/2013. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 08/04/2013 ClinicalTrials.gov ID: NCT01237340 Study Identification Unique Protocol ID: EMR 701048-009 Brief Title:
More informationWhat s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance
Vol. 9, No. 2, February 2013 Happy Trials to You What s New in GCP? FDA Clarifies, Expands Safety Reporting Guidance Reprinted from the Guide to Good Clinical Practice with permission of Thompson Publishing
More informationREGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts
REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you
More informationAdverse Event Reporting: During the Study
Vol. 5, No. 8, August 2009 Can You Handle the Truth? Adverse Event Reporting: During the Study By S. Eric Ceh The reporting of adverse events (AEs) is a standard task for investigative sites involved in
More informationAnnual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014
Annual Research Administrators Symposium IRB Compliance Thursday, July 31, 2014 Why IRB Compliance Is Required for Grant Submissions Topics to Cover Today What is an IRB? Why IRB review is required? Regulatory
More information3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor
POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities
More informationWhat s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials
Vol. 14, No. 10, October 2018 Happy Trials to You What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials While multiple, concurrently accruing patient cohorts in first-in-human (FIH)
More informationDana-Farber/Harvard Cancer Center Site Management Plan
Dana-Farber/Harvard Cancer Center Site Management Plan 1.0 Oversight Responsibilities of the Overall Principal Investigator and Site Responsible Investigator A system using an Overall Principal Investigator
More informationUnderstanding Reporting Obligations to the IRB
Understanding Reporting Obligations to the IRB fully accredited since 2006 May 13 & 15, 2014 Mitchell E. Parrish, JD, RAC, CIP Regulatory Attorney 2 3 WEBINAR HOUSEKEEPING Questions & Answers Feel free
More informationIND Development Process Published on ResearchGo UCLA (
IND Development Process IND Development Overview The Pre-IND Process The IND Study Protocol Preparing the Initial IND Submission Filing the IND Maintaining the IND IND Templates, Education and Useful Links
More informationInvestigational New Drug Applications: two cases
Investigational New Drug Applications: two cases April 15, 2009 Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More information10-CBA providing access to unlicensed cord blood units
10-CBA providing access to unlicensed cord blood units Using the NMDP IND to access unlicensed cord blood units Amy Hays, Sr. Clinical Research Specialist, CIBMTR History of CBUs First CBU transplant done
More informationClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
More informationLong-Term Follow-Up in Gene Transfer Clinical Research
Long-Term Follow-Up in Gene Transfer Clinical Research Jan P. Vleck, MD CIP Institutional Biosafety Committee Services A Division of WIRB www.ibcservicepoint.com ibcs@wirb.com What is LTFU? the collection
More informationClinicalTrials.gov Registration Guide
ClinicalTrials.gov Registration Guide The Food and Drug Administration Amendments Act (FDAAA), National Institutes of Health (NIH) and International Committee of Medical Journal Editors (ICMJE) require
More informationHuman Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationHuman Research Protection Program Policy
Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving
More informationDevice research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.
POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: A DF/HCC Investigator who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities that
More informationInvestigator s Handbook
Page 96 CHAPTER 11 Investigational Drugs, Agents, Biologics, and Devices Investigational Drugs/Investigational Biologics (Test Articles) A new drug/agent or biologic that is used in a clinical investigation.
More informationThe Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
More informationSOP#: Original Approval Date: 3/25/13
STANDARD OPERATING PROCEDURE EXTERNAL SAFETY REPORTS - COOPERATIVE GROUP STUDIES SOP#: 6.2.5 Original Approval Date: 3/25/13 Version#: 1.0 Current Revision Date: n/a 1.0 PURPOSE/BACKGROUND The purpose
More informationMaking Sense of Reporting Obligations to the IRB. fully accredited since 2006
Making Sense of Reporting Obligations to the IRB fully accredited since 2006 Webinar Housekeeping Questions & Answers Feel free to submit questions at any point during the webinar using the chat box
More informationUS Special Operations Command Human Research Protection Office
S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More informationTITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17
SOP #: INV-100 Page: 1 of 5 1. POLICY STATEMENT: DF/HCC research pharmacies follow a standard set of policy requirements for clinical trials. 2. BACKGROUND: None 3. RESPONSIBLE PERSONNEL: 3.1. Research
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationGemzar (gemcitabine) is currently approved in adult patients for use in the treatment of:
INTRODUCTION Hospira, Inc. submitted a 505(b)(2) NDA (200-795) for Gemcitabine Injection on December 11, 2009. The Reference Listed Drug (RLD) is Gemzar (gemcitabine hydrochloride) Injection, Powder, Lyophilized,
More informationActelion Pharmaceuticals Ltd. Gewerbestrasse 16 Allschwil 4123 Switzerland
Trial information Subject disposition Subject analysis sets Baseline characteristics End points Adverse events More information TRIAL INFORMATION Trial identification Eudract number Sponsor protocol code
More informationMCW Office of Research Standard Operating Procedure
MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DRUGS AND BIOLOGICS Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW/FH Faculty
More informationDemystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?
Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination
More informationTitle: Review of Medical Devices Page: 1 of 5 Written by:
THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,
More informationGUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS
1. PURPOSE This guideline is about the collection, verification, and submission of the reports of adverse events / reactions occurring in clinical drug trials, and code breaking methods. 2. DEFINITIONS
More informationPOLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011 Research investigating or evaluating drugs, biologics or devices must
More informationTerry Sousa UMass Medical School PRS Administrator for Clinicaltrials.gov
Terry Sousa UMass Medical School PRS Administrator for Clinicaltrials.gov What is ClinicalTrials.gov? National registry of federally and privately supported research studies Why register and report results?
More informationRole of Academic Investigators in Drug Development
DTRCS Regulatory Education Seminar, June 12, 2007 Role of Academic Investigators in Drug Development Howard Lee, MD, PhD Associate Adjunct Professor Director, Center for Drug Terminology Sponsor Investigator
More informationCancer Center Clinical Trials Office
STANDARD OPERATING PROCEDURE MANAGEMENT OF EXPANDED ACCESS & TREATMENT USE PROTOCOLS SOP#: 2.3 Original Approval Date: 8/27/15 Version#: 2.0 Current revision Date: 2/20/18 1.0 PURPOSE/BACKGROUND Expanded
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR Assessing Protocol Feasibility
Date of version: 01 April 2012 Replaces previous version: 201.01 01 June 2011 Study Start-Up SS-201.02 STANDARD OPERATING PROCEDURE FOR Assessing Protocol Feasibility Approval: Nancy Paris, MS, FACHE President
More information1 Purpose. 2 Procedure. Title: FDA-Regulated Research. SOP Number: 1301 Effective Date: June 2, Previous Version Dates:
Previous Version Dates: Title: FDA-Regulated Research SOP Number: 1301 Effective Date: June 2, 2017 1 Purpose FDA regulations apply to research that involves a FDA-regulated test article in a clinical
More informationWarning Letter. We note that you are the sponsor and the clinical investigator for Studies 1 and 2, while a third party is the sponsor of Study 3.
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Bv Certified Mail - Return Receipt Reauested And Bv Facsimile Transmission Food and Drug Administration Center for Biikqii Evaluation and Research
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationFDA Audit Preparation
Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits
More informationGood Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ
Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of
More informationCONTACT INFORMATION. PHRC Office. Josephine O Driscoll-Davis. Michael Ducey
PHRC Office CONTACT INFORMATION 116 Huntington Ave., 10 th Floor Boston, MA 02116 http://healthcare.partners.org/phsirb Josephine O Driscoll-Davis Assistant Director Administrative Chair (617) 424-4107
More informationInvestigator Guide Reporting of Unanticipated Problems to the IRB
Committee for Protection of Human Subjects The IRB for New York Medical College, Westchester Medical Center, Metropolitan Hospital Center (HHC), and Westchester Institute for Human Development, Terence
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationImplementing Good Clinical Practice at an Academic Research Institution
Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More information1 of 5 11/6/2014 3:08 PM
1 of 5 11/6/2014 3:08 PM : Thursday, November 6, 2014 1:07:42 PM : NU SF: Basic Information 1. * Title of study: Biomedical Research Study 2. * Short title: Biomedical Study 3. * Brief description: This
More information2200 Santa Monica Boulevard Santa Monica, California 90404
..- DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service cwis6 1 AIII)~tant Food and Drug Administration Center for Biologica E~eluation Evaluation and Research 1401 Rockville Rockvilie Pike Rockville
More informationGuidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection u.s. Department of Health and Human Services Office of the Commissioner (OC) Center
More informationAmarex Clinical Research Washington DC metro area A Product Development Services Company. From Lab to Market Approval
Amarex Clinical Research Washington DC metro area A Product Development Services Company Regulatory Strategy From Lab to Market Approval Strategy Implementation Pre-Clinical Assays Global Clinical Trials
More informationSponsoring an IND? Ignorance is Not Always Blissful
Translational Science 2013 Navigating The FDA Regulatory Landscape April 19, 2013 Washington D.C. Sponsoring an IND? Ignorance is Not Always Blissful Lisa A. Speicher, Ph.D Director, Clinical Trials Office
More information11.0 FDA-Regulated Research
11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationExpanded Access (including Emergency Use & Humanitarian Use Devices)
Expanded Access (including Emergency Use & Humanitarian Use Devices) Bertha delanda, CIP IRB Training Specialist Research Compliance Office March 2012 What Is Expanded Access? Permits use of an investigational
More informationPREP Workshop # 20: Investigational Drug Accountability. Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS
PREP Workshop # 20: Investigational Drug Accountability Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS CME Disclosure Statement The North Shore LIJ Health System adheres
More informationDARTMOUTH COLLEGE BIOLOGICAL SAFETY PROGRAM Institutional Biosafety Committee Subcommittee for Clinical Gene Transfer
INSTITUTIONAL BIOSAFETY COMMITTEE SUBCOMMITTEE FOR CLINICAL GENE TRANSFER (IBC-SCGT) CHARTER Approval Date: 12.18.14 Version: 1 DARTMOUTH COLLEGE BIOLOGICAL SAFETY PROGRAM Institutional Biosafety Committee
More informationVanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
December 8, 2016 C2012 Web Seminar Series Identifying and Reporting Protocol Deviations Vanessa Laroche, CCRC, CCRA, CIP, CQA Quality Assurance Specialist Technical Resources International (TRI), Inc.
More informationHCCA 13 TH ANNUAL COMPLIANCE INSTITUTE LAS VEGAS, NV APRIL 29, 2009
HCCA 13 TH ANNUAL COMPLIANCE INSTITUTE LAS VEGAS, NV APRIL 29, 2009 MEDICARE COVERAGE ANALYSIS WORKSHOP: THE HOW TO OF MEDICARE COVERAGE IN RESEARCH Suzanne LivPage, J.D. Director, Clinical Research Initiation
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More informationSafety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs)
Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs) Version 1.4 Effective date: 1 December 2011 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision
More informationUniversity of California, Irvine Human Research Protections Standard Operating Policies and Procedures
University of California, Irvine Human Research Protections Standard Operating Policies and Procedures Policy Number: 41 Title: Investigational Drugs, Agents, and Biologics Date of Last of Revision: 07/28/2006;
More informationDRUG ORDERING AND MAINTENANCE
AND MAINTENANCE Disclaimer: Please note that the instructions provided in this chapter mainly apply to agents provided by the Pharmaceutical Management Branch (PMB), of Cancer Therapy Evaluation Program
More informationTo document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD COMPASSIONATE/TREATMENT USE OF MEDICAL DRUGS, BIOLOGICS AND DEVICES I. PURPOSE To document the review procedures for a submission
More informationSOP NUMBER: SC-404 Page 1 of 3
STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Last Revised: 1/2016 Prior Version: None Title: Transporting Investigational Product to Other Sites SOP NUMBER: SC-404 Page 1 of 3 1. PURPOSE: UHCMC
More informationThe Johns Hopkins Institute for Clinical and Translational Research
ICTR The Johns Hopkins Institute for Clinical and Translational Research INTRODUCTION TO CLINICALTRIALS.GOV LINDA POST, RN, BSN, CCRP RESEARCH NAVIGATOR JUNE 28, 2013 Development of this resource was supported
More informationUniversity of California, San Francisco Helen Diller Family Comprehensive Cancer Center. Policy for Centralized IND/IDE Management
University of California, San Francisco Policy for Centralized IND/IDE Management Purpose The purpose of this policy is to outline how the Clinical Research Support Office (CRSO) centrally manages and
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More information